Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;14(2):111-116.
doi: 10.1136/neurintsurg-2020-017193. Epub 2021 Feb 16.

Is a picture-perfect thrombectomy necessary in acute ischemic stroke?

Collaborators, Affiliations

Is a picture-perfect thrombectomy necessary in acute ischemic stroke?

Ching-Jen Chen et al. J Neurointerv Surg. 2022 Feb.

Abstract

Background: The benefit of complete reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 3) over near-complete reperfusion (≥90%, mTICI 2c) remains unclear. The goal of this study is to compare clinical outcomes between mechanical thrombectomy (MT)-treated stroke patients with mTICI 2c versus 3.

Methods: This is a retrospective study from the Stroke Thrombectomy and Aneurysm Registry (STAR) comprising 33 centers. Adults with anterior circulation arterial vessel occlusion who underwent MT yielding mTICI 2c or mTICI 3 reperfusion were included. Patients were categorized based on reperfusion grade achieved. Primary outcome was modified Rankin Scale (mRS) 0-2 at 90 days. Secondary outcomes were mRS scores at discharge and 90 days, National Institutes of Health Stroke Scale score at discharge, procedure-related complications, and symptomatic intracerebral hemorrhage.

Results: The unmatched mTICI 2c and mTICI 3 cohorts comprised 519 and 1923 patients, respectively. There was no difference in primary (42.4% vs 45.1%; p=0.264) or secondary outcomes between the unmatched cohorts. Reperfusion status (mTICI 2c vs 3) was also not predictive of the primary outcome in non-imputed and imputed multivariable models. The matched cohorts each comprised 191 patients. Primary (39.8% vs 47.6%; p=0.122) and secondary outcomes were also similar between the matched cohorts, except the 90-day mRS which was lower in the matched mTICI 3 cohort (p=0.049). There were increased odds of the primary outcome with mTICI 3 in patients with baseline mRS ≥2 (36% vs 7.7%; p=0.011; pinteraction=0.014) and a history of stroke (42.3% vs 15.4%; p=0.027; pinteraction=0.041).

Conclusions: Complete and near-complete reperfusion after MT appear to confer comparable outcomes in patients with acute stroke.

Keywords: stroke; thrombectomy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MRL: Grants from the NIH (R01NS105692, R01NS088072, U24NS100654, UL1TR002319, R25NS079200) and the American Heart Association (18CDA34110295). Unrestricted educational grants from Medtronic, Stryker and Philips Volcano. Consultant for Medtronic. Minor equity/ownership interest in Proprio, Cerebrotech, Synchron. Adviser to Metis Innovative. JAG: Grants from the Georgia Research Alliance. Consultant for Cognition Medical. AJY: Grants from Medtronic, Cerenovus, Penumbra, and Stryker. Consultant for Penumbra and Cerenovus. Equity interest in Insera Therapeutics. RWC: Proctor for Medtronic and Cerenovus. AMS: Research support from Penumbra, Stryker, Medtronic, and Siemens. Consultant for Penumbra, Stryker, Terumo, and Arsenal. MM: Consultant for Medtronic and Cerenovus. Stock ownership in Serenity Medical, Synchron, and Endostream. RMS: Grants from the NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, the NIH (R01NS111119-01A1, UL1TR002736, KL2TR002737), the National Center for Advancing Translational Sciences, the National Institute on Minority Health and Health Disparities, and Medtronic. Consultant for Penumbra, Abbott, Medtronic, InNeuroCo and Cerenovus. Others: None.

Figures

Figure 1
Figure 1
(A) 90-day mRS distributions of unmatched mTICI 2c versus 3 cohorts. (B) 90-day mRS distributions of matched mTICI 2c versus 3 cohorts. mTICI, modified Thrombolysis in Cerebral Ischemia; mRS, modified Rankin Scale.
Figure 2
Figure 2
Subgroup analyses of primary outcome according to reperfusion status of the matched mTICI 2c vs 3 cohorts. IV-tPA, intravenous tissue plasminogen activator; mRS, modified Rankin Scale; ASPECT, Alberta Stroke Program Early CT; ICA, internal carotid artery; mTICI, modified Thrombolysis in Cerebral Ischemia; NIHSS, National Institute of Health Stroke Scale; SR, stent retriever. *Adjusted for age, sex, atrial fibrillation, ASPECT score, NIHSS score, primary vessel occlusion location, symptom onset to puncture time, number of attempts, IV tissue plasminogen activator administration, pre-stroke mRS, and primary mechanical thrombectomy technique.

References

    1. Rha J-H, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38:967–73. - PubMed
    1. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016;387:1723–31. - PubMed
    1. Chen C-J, Ding D, Starke RM, et al. Endovascular vs medical management of acute ischemic stroke. Neurology 2015;85:1980–90. - PMC - PubMed
    1. Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012;380:1231–40. - PMC - PubMed
    1. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012;380:1241–9. - PubMed